US equities |
MU $1,029.00 ▼-0.66% NVDA $229.28 ▼-0.52% SPCX $162.57 ▲+1.25% TSLA $382.70 ▲+2.05% AAPL $336.64 ▼-1.11% MSFT $535.07 ▲+2.38% AMZN $262.43 ▲+3.29% META $718.67 ▼-0.31%
FinancialContent

Moderna, Inc. - Common Stock (NQ:MRNA)

225.00 +28.00 (+14.21%)
Delayed Quote Updated: 4:00 PM EDT, Oct 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna, Inc. - Common Stock

< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
99 100 Next >
These S&P500 stocks are moving in today's pre-market session ↗
Via Chartmill
MRNA Vs NVAX: Which Vaccine Stock Is Wall Street More Bullish On Right Now? ↗
Via Stocktwits
News headline image
Why Moderna Stock Surged Today ↗
The vaccine maker is expanding beyond its COVID-focused offerings. 
Via The Motley Fool
These S&P500 stocks are moving in today's after hours session ↗
Via Chartmill
Discover which S&P500 stocks are making waves on Wednesday. ↗
Via Chartmill
ABUS Stock On Track For Biggest Intraday Drop In Over 5 Years – What’s The Issue Around Its Patent In Europe? ↗
Via Stocktwits
Topics Intellectual Property
Gapping S&P500 stocks in Monday's session ↗
Via Chartmill
News headline image
Moderna Stock Skyrockets To 52-Week High: What&#39;s Behind The Surge? ↗
Moderna Inc (NASDAQ:MRNA) shares are trading higher on Wednesday on continued momentum after the company's Tuesday update revealing the long‑term results from a cancer therapy study. 
Via Benzinga
What's going on in today's session: S&P500 movers ↗
Via Chartmill
News headline image
Moderna (MRNA) Shares Skyrocket, What You Need To Know
Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 8.8% in the afternoon session after the company, in partnership with Merck, announced positive results from a five-year follow-up study of... 
Via StockStory
Topics Artificial Intelligence Government
News headline image
Moderna Stock Still Worth 37% Less After Cancer Vaccine Data? BofA’s New Price Target Keeps Retail Traders Cautious ↗
BofA Securities said the target hike reflects higher sales expectations, despite logistics challenges. 
Via Stocktwits
News headline image
Moderna Pops 17%—Is There Life in MRNA, Down 90% from COVID High? ↗
Via MarketBeat
News headline image
Moderna Shares Rise On Five-Year Follow-Up Takeaways For Skin Cancer Vaccine: Retail Applauds ‘Solid’ Update ↗
Intismeran autogene vaccine, in combination with cancer drug Keytruda, reduced the risk of recurrence or death at five years of follow-up, the company said. 
Via Stocktwits
News headline image
Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following
Via ACCESS Newswire
News headline image
3 Healthcare Stocks Walking a Fine Line
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, and... 
Via StockStory
Topics Stocks
Exploring the top movers within the S&P500 index during today's session. ↗
Via Chartmill
These S&P500 stocks are moving in today's session ↗
Via Chartmill
News headline image
The mRNA 2.0 Inflection: A Deep Dive into Moderna (MRNA) as it Faces a Critical 2026
As of January 16, 2026, Moderna, Inc. (NASDAQ: MRNA) stands at a critical crossroads. Once the poster child for the biotechnology industry’s rapid response to a global pandemic, the Cambridge-based... 
Via Finterra
Topics Initial Public Offering Intellectual Property Lawsuit
Top S&P500 movers in Friday's pre-market session ↗
Via Chartmill
Chips and Checks: AI and Banks Lead Wall Street's Charge ↗
Via Chartmill
Topics Artificial Intelligence
News headline image
The Execution Engine: How Merck is Dominating the 2026 Pharma Landscape
As of January 15, 2026, Merck & Co. (NYSE: MRK) has emerged as the standout performer in the pharmaceutical sector, defying the gravity of looming patent expirations with a series of strategic... 
Via MarketMinute
Topics Economy Intellectual Property
News headline image
Moderna’s High-Stakes Transformation: Navigating the Post-Pandemic Pivot
Once the poster child for the biotechnology sector’s rapid response to the global pandemic, Moderna, Inc. (Nasdaq: MRNA) finds itself at a critical crossroads in early 2026. After a tumultuous period... 
Via Finterra
Topics Initial Public Offering Intellectual Property
Trump’s Iran Tariff Threat Lit a Fuse Under Oil — and Wall Street Still Sold It ↗
Via Chartmill
Topics Government
These S&P500 stocks are moving in today's session ↗
Via Chartmill
Stay informed with the top movers within the S&P500 index on Tuesday. ↗
Via Chartmill
News headline image
The mRNA Pivot: Moderna Navigates Regulatory Headwinds and Tariff Turmoil in a Volatile 2026 Biotech Landscape
As the 44th Annual J.P. Morgan Healthcare Conference concludes in early January 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a critical crossroads. Once the darling of the pandemic era, the... 
Via MarketMinute
Topics Economy Intellectual Property World Trade
Top S&P500 movers in Monday's session ↗
Via Chartmill
What's going on in today's session: S&P500 movers ↗
Via Chartmill
These S&P500 stocks are moving in today's pre-market session ↗
Via Chartmill
News headline image
Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
Via ACCESS Newswire
< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
99 100 Next >